Vimta Labs Limited has informed the Exchange about Investor Presentation.
Vimta Labs Limited Registered Office 142, IDA Phase II, Cherlapally Hyderabad-500 051 Telangana, India T: +91 4027264141 F : +91 40 2726 3657
VLL\SE\076\2024-25 Date: 24.01.2025
B S E Limited, P J Towers, Dalal Street, Mumbai: 400001. Scrip Code No.524394
Dear Sir/Madam,
-
Vimta
Driven by Quality. Inspired by Science.
National Stock Exchange of India Limited, “Exchange Plaza”, Bandra, Kurla Complex, Bandra (E), Mumbai 400051. Trading Symbol: VIMTALABS
Reg:
Investor Presentation —Q3 results — FY 202
5
to provisions of Regulation 30 of the SEBI
Pursuant (Listing Obligations and Disclosure Requirements) Regulations, 2015 the “Listing Regulations”) we are enclosing herewith the Investor Presentation.
Further, pursuant to Regulation 46 of the Listing Regulations, the aforesaid information will be available on the website of the Company i.e., https: vimta.com/investor-presentatio
This is for your information and necessary records.
For VIMTA LABS LIMITED
Su ani Vasireddi Company Secretary
Arachments: as above.
Life Sciences Campus,# 5, MNScience&TechnologyPark, Genome Valley, Shamirpet,Hyderabad-500101,Telangana,lndia T: +91 40 6740 4040 E mdoffice@vimta.com URL www.vimta.com
-
C I N : L 2 4 1 1 0 T G 1 9 9 0 P L C 0 1 1 9 7 V Vimta Labs Limited
Investor Presentation Q3 & 9M FY25
Disclaimer
The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.
This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global industries that we serve, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employees have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.
No part of this presentation may be reproduced, quoted or circulated without prior written approval from Vimta Labs Ltd.
2
Table of Content
Q3 & 9M FY25 Earnings
Company Overview
Industry Landscape
Our Competitive Advantage
Way Forward
Q3 & 9M FY25 Earnings
Q3 & 9M FY25 Highlights
Key Metrics: Q3 & 9M FY25
Profit & Loss Statement
Balance Sheet
Financial Track Record
Shareholding Pattern
4
Q3 FY25 Highlights
Rs 911 Mn
Total Income
Rs 343 Mn Margin 37.6% EBITDA
Rs 239 Mn
PBT
Rs 7.9
EPS
Rs 657 Mn
CAPEX
Rs 175 Mn Margin 19.2% PAT
5
9M FY25 Highlights
Rs 2,521 Mn
Total Income
Rs 915 Mn Margin 36.3% EBITDA
Rs 21.8
EPS
Rs 958 Mn
CAPEX
Rs 640 Mn
PBT
Rs 484 Mn Margin 19.2% PAT
0.03x
Debt to Equity Ratio
Rs 113 Mn (December 31st 2024) Total Debt
Rs 180 Mn (December 31st 2024)
Cash and Cash Equivalents
6
Key Metrics: Q3 FY25
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
21.1% YoY
39.4% YoY
32.7%
37.6%
35.8%
753
854
911
246
306
343
19.2%
43.0% YoY
16.3%
19.9%
123
170
175
200
175
150
125
100
75
50
25
-
25%
20%
15%
10%
5%
0%
5
0
5.5
7.7
7.9
Q3FY24
Q2FY25
Q3FY25
Q3FY24 Q2FY25 Q3FY25
Q3FY24 Q2FY25 Q3FY25
Q3FY24 Q2FY25 Q3FY25
7
Key Metrics: 9M FY25
Total Income (In ₹ Mn)
EBIDTA & EBIDTA Margin (In ₹ Mn, %)
PAT & PAT Margin (In ₹ Mn, %)
Basic EPS (In ₹)
EBIDTA
EBIDTA Margin
PAT
PAT Margin
15.0% YoY
28.1% YoY
32.6%
36.3%
2,192
2,521
715
915
39.0% YoY
15.9%
19.2%
349
484
525
500
475
450
425
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
-
25%
20%
15%
10%
5%
0%
15.7
21.8
9MFY24
9MFY25
9MFY24
9MFY25
9MFY24
9MFY25
9MFY24
9MFY25
8
Profit & Loss Statement
Particulars (₹ Mn)
Revenue from Operations
Other Income
Total Income
Material and Testing Costs
Cost of lab setup
Changes in inventories of work-in-progress
Employee benefits expense
Other expenses
Total Expenses
EBIDTA
EBIDTA (%)
Finance costs
Depreciation expense
Profit before tax
PBT (%)
Tax
Profit for the year
PAT (%)
Basic EPS (INR)
Q3 FY25 899
Q3 FY24 746
YoY (%) Q2 FY25 847
QoQ(%)
9M FY25 2,495
9M FY24 2,159
YoY (%)
33
2,192
15.0%
12
911
204
2
0
234
128
568
343
7
753
151
0
0
230
125
507
246
37.6%
32.7%
6
98
239
5
84
156
26.2%
20.8%
64
175
34
123
19.2%
16.3%
7.9
5.5
21.1%
39.4%
52.9%
43.0%
7
854
182
2
0
239
126
548
306
35.8%
4
83
219
25.6%
49
170
19.9%
7.7
6.7%
12.2%
9.3%
2.9%
26
2,521
529
4
0
698
376
1,606
915
36.3%
15
261
640
440
2
0
677
358
1,477
715
32.6%
16
253
446
25.4%
20.3%
155
484
19.2%
21.8
97
349
15.9%
15.7
28.1%
43.5%
39.0%
9
Financial Track Record
TOTAL INCOME (₹ Mn)
PROFITABILITY (₹ Mn)
1,837 2,115 2,797 3,216 3,223 2,521
11.9% CAGR
EBITDA & EBITDA Margin
PAT & PAT Margin
36%
25%
29%
31%
28%
18%
330
538
817
984
908
915
22.4% CAGR
4%
68
10%
214
19%
15% 15%
13%
413
482
410
484
43.2% CAGR
FY20
FY21
FY22
FY23
FY24 9MFY25
FY20
FY21
FY22
FY23
FY24
9MFY25
FY20
FY21
FY22
FY23
FY24 9MFY25
Total Revenue
EBIDTA
EBIDTA Margin
PAT
PAT Margin
RoE (%)
RoCE (%)
Debt to Equity
Total Capex
BALANCE SHEET RATIOS
4%
11%
18%
17%
13%
13%
15% 18% 25% 22% 16% 17%
0.16
0.16
0.08
0.05
0.06
0.03
166
357
450
492
763
958
FY20
FY21
FY22
FY23
FY24 9MFY25
FY20
FY21
FY22
FY23
FY24 9MFY25
FY20
FY21
FY22
FY23
FY24 9MFY25
FY20
FY21
FY22
FY23
FY24 9MFY25
a. b.
Financial numbers for the period 9MFY25 are from continuing operations and exclude Diagnostic and Pathological services business CAGR for the period FY20-FY24
10
Shareholding Pattern
Shareholding as on 31st December 2024
Others 58.3%
Promoters 36.8%
DII 1.2%
FII 3.8%
Source: NSE & BSE
#Cash and Cash equivalents includes other bank balances
Share Information as on 31st December 2024
NSE Ticker
BSE Ticker
Market Cap (INR Cr)
% free-float
Free-float market cap (INR Cr)
Total Debt (INR Mn)
Cash & Cash Equivalents (INR Mn)
Shares Outstanding
3M ADTV (Shares)*
3M ADTV (INR Cr)*
Industry
VIMTALABS
524394
2,170.24
63.24%
1,372.49
113
180
2,22,13,279
1,89,254
15.9
TIC
11
Company Overview
Vimta at a Glance
Our Journey
Services
Geographical Presence
Management
12
Vimta at a Glance
Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high- quality, cutting-edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro-chemicals, food & beverages, electronics, medical devices, home and personal care products, and environment testing.
40 Years
Of experience in CRTO industry
1,300+
Dedicated Multi- Disciplinary Team
600,000+
Sq. Ft. of Ultra-modern lab spaces
10
Labs and Offices across India
90+
Successful Regulatory Audits
13
Our Journey
Infrastructure
People
Investment
Capabilities
2024
600,000+ ft2
1300+
492 M
2015
400,000+ ft2
1000+
580 M
Pharma & Biopharma: Discovery & development services; Food; Environment; Electronics Testing
Analytical – Pharma, Biopharma & Food; Clinical Research; Preclinical; Clinical Diagnostics; Environment Testing
Revenue s
3,216 M
1,073 M
2006
1992
200,000+ ft2
600+
992 M
Clinical Research; Environment; Analytical Testing – Food & Pharma
542 M
50,000+ ft2
150+
85 M
Environment; Analytical – Food & Pharma; Toxicology; Material testing; Clinical Research
16 M
1984
500 ft2
6
200,000
Minerals & ores; Metals; Rice bran oil testing
156,000
• •
Investment & Revenues in INR Investments depicted may have spread across more than the denoted year
14
Our offerings
Drug discovery and development services
Food & Agri Testing
Electronics & Electricals Testing
Environment Testing & Consultancy
15
1. Drug discovery and development services
Offerings
Industry
Pharma Analytical
Clinical Research
Preclinical Research
Pharmaceuticals, Biologics, Nutraceuticals, Medical Devices, Animal Health
Pharmaceuticals, Biologics, Medical Device, Agrochemical, Speciality Chemicals
Accreditations & Regulatory Approvals
DCA, USFDA, WHO, EMA, DRAs of Ukraine, Turkey
CDSCO, USFDA, WHO, MHRA, NPRA, and European DRAs
OECD-GLP, CCSEA, DSIR, AAALAC
Wide range of analytical services E&L studies Stability testing Method
Microbiology Immunogenecity
studies
Characterization Bioassays
Services
development
Validations Genotoxic impurities
Elemental analysis In vitro studies Physical
Characterisation Dissolution Testing
▪ BA/BE Studies ▪ Bioanalytical ▪ Clinical Trials (Phase I to IV) ▪ Clinical End Point Studies ▪ Claim Studies
Comprehensive in vitro, ex vivo and in
vivo studies ADME, and PK IND enabling packages (genetic
toxicology, safety pharmacology, general toxicology, & toxicokinetic studies).
Chronic toxicology, reproductive
toxicology, neurotoxicology, immunotoxicology, and carcinogenicity
Biowaiver and alternative to animal
studies
Ecotoxicology, environmental fate and
metabolism studies
16
2. Food & Agri Testing
Industry
Food Manufacturing & Processing, Cultivation, Export, Retail, Neutraceuticals, Agro-chemicals, Water & Beverages, Animal Feed
No. of Locations
7 (Hyderabad, Mumbai (NFL), Ahmedabad, Bengaluru, Nellore, Nashik, Noida)
Accreditations & Regulatory Approvals
• FSSAI, ISO 17025, BIS, APEDA, EIS, SHEFEXIL, EU Commission, OCED-GLP, AGMARK, Tea Board, Spices Board • Hyderabad Lab is a National Reference Lab for Water & Beverages Testing • Mumbai Lab is a National Food Laboratory, operated for FSSAI
Services
Food contaminants, food allergens, microbiology/pathogen, GMO testing, nutrition & composition analysis for all
agri, food, food products, water and beverages New product development support, validations Shelf life assessments Packaging material testing Nutraceuticals testing, method validations Animal feed analysis Argo-chemical (crop sciences): support for research and development, method development, validation and
testing for regulatory submissions in India, Europe, South America, Japan, South East Asia
17
3. Electricals & Electronics Testing & Certification
Industry
Aviation, Defence, Medical Device, Telecom, Home appliances, Toys, Industrial & control equipment, Consumer electronics, Rail & Automotive, IT, IOT, physical security products, and allied industries
No. of Laboratories
Accreditations & Regulatory Approvals
Services
1 (Hyderabad)
ISO 17025, TEC BIS & NABCB (of Emtac Laboratories Pvt Ltd., fully owned subsidiary)
EMI/EMC testing Radio Frequency testing Environmental & reliability testing Mechanical & electrical safety testing Performance testing Product Certification CE marking
18
4. Environment Testing & Consultancy Services
Industry
No. of Locations
Accreditations & Regulatory Approvals
Services
Manufacturing and Processing industries, Oil & Gas, Power, Cement, Mining, Infrastructure, etc.
4 (Hyderabad, Chennai, Kolkata and Noida)
MoEF, ISO 17025, QCI/NABET, OSHAS 45000
Post project monitoring Industrial hygiene & Indoor air Advanced testing & tailor-made services (CEMS validation, PG for pollution equipment, Dioxins, Furans,
Industrial Gas, VOC as per LEED and EPA)
Offshore monitoring SIA & hydrogeological studies EHS audits, Hazardous waste study, Life cycle assessment Due diligence studies Green audit, Metrological studies Noise, air, traffic modelling etc.
19
Geographical Presence
Hyderabad (Headquarters)
Food
Pharma
Electronics & Electrical
Environment
Electrical and Electronics
Hyderabad
Food
Environment
Hyderabad
Ahmedabad
Noida
Mumbai (NFL)
Nashik
Bengaluru
Nellore
Hyderabad
Chennai
Noida
Kolkata
20
Key Management Team
S P Vasireddi Executive Chairman
Harita Vasireddi Managing Director
Sreenivas Neerukonda Executive Director
Harriman Vungal Executive Director - Operations
Dr. S P Vasireddi is a Scientist – Technocrat – Entrepreneur having more than 45 years of experience in contract research and testing laboratory management. He is the founder and Chairman of VIMTA.
Dr. Vasireddi is reckoned as the pioneer of CRO industry in India. He led VIMTA from a single bench laboratory to a wide spectrum, globally recognized CRTO. In recognition of his eminence in CRO & Testing industry he is/has been nominated as a member on the Advisory/ Governing Boards of several apex scientific and regulatory bodies of the country such as FSSAI, NABL etc.
Harita has close to 25 years of experience in the TIC/CRO industry with track record of growth and profitability.
Her Core competencies include management & driving organizational adaptabilty and development, quality management systems, and risk management.
She holds an MBA in Operations Management from Boston College, USA; and is a B.Pharm graduate from Mysore university, India
Sreenivas’s core competencies include strategic planning and execution, new service opportunities development, communication and relationship building, competitive intelligence, and fostering strong team relations to deliver goal- oriented performance.
He holds an MBA in Management Information Systems, University of Oklahoma, USA; B.Pharm, Nagpur University, India.
Harriman was inducted to the Board as one of the Promoter Directors in 1990 and was appointed as Technical Director of the Company in 1992. He has extensive lab operations management experience and is a go to senior resource on GXPs.
He has led the Company’s effort in building state of the art IT infrastructure, systems and their compliance to applicable regulations.
He holds D. Tech in Electronics from Toronto, Canada.
21
Industry Landscape
Market Opportunity
Factors Driving Industry Growth
22
Markets Opportunity
l a b o G
l
)
n B D S U
(
n a i d n I
)
n B D S U
(
Pharmaceutical & Biopharmaceuticals
Preclinical
Food Testing
Environment Testing
Electronics Testing
957.6
127.3
40.5
20.2
13.4
405.5
76.6
19.5
11.1
6.8
2020 | 2028 CAGR: 11.3%
2023 | 2028 CAGR: 10.7%
2022 | 2032 CAGR: 7.5%
2022 | 2030 CAGR: 7.8%
2021 | 2031
CAGR: 7.1%
Pharmaceutical & Biopharmaceuticals
130.0
Preclinical
Food Testing
Environment Testing
Electronics Testing
1.0
0.6
0.9
0.4
0.2
42.0
0.5
2021 | 2030
CAGR: 13.4%
2021 | 2030
CAGR: 7.5%
2022 | 2027
CAGR: 9.3%
2021 | 2026
CAGR: 9.9%
0.1
0.05
2021 | 2028
CAGR: 8.6%
23
Factors Driving Industry Growth
Drug Discovery & Development
Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry
Specialized knowledge, skills and testing tools that CROs can provide
Food Testing
Growing international food regulations, evolving Indian food safety regulations, growing world population, and increasing demand for independent third-party inspection & testing
Electrical & Electronics Testing
Surge in demand for certification services of electrical & electronic products, growing defence budgets and make in India initiatives
Green push by Government for electrical vehicles
Environment Testing
Increase in regulations to address the growing concerns of air, water and soil contamination
24
Our Competitive Advantage
Our Position in the CRTO
Landscape
Our Strength
25
Our Position in the CRTO Landscape
Pharma Analytical
Food Testing
#1 in India
#1 in India
Customers – 90% of India top 20
36% revenues from overseas
Serving 7 of India’s top 10 food companies
The only private EU commission approved lab in India
Clinical Research
Preclinical
Among the most reputed CROs in India
Amongst Top 5 in India
75% of revenues from overseas
Electronics & Electricals
Start-up
Environment
Among top 5 in India
Customers – PSUs, large corporations across industries
26
Our Strengths
Infrastructure
Unparalleled lab infrastructure in the country. Gold LEED certified Vivarium
Customer Centricity
Long term partnerships with customers
Strong culture of quality and compliance
Compliance
Long & successful regulatory track record – cGMP, GLP, GCP
Compliance
Innovations
Strong culture of quality and compliance
Continuous addition of services and evolving excellence
Knowledge
Multi-disciplinary, knowledgeable, skilled and trained manpower
Technology
Wide range of state-of-the-art technologies and scalable capacities
27
Way Forward
Our Key Growth Drivers &
Strategies
28
Our Key Growth Drivers & Strategies
Favourable markets
Core business strategies
Core operational strategies
Best practices
✓ Growth momentum
✓ Capacity expansions
in markets
✓ Growing demand for safe & quality - drugs, food, diagnostics, electronics & clean environment
✓ Service innovations
✓ Penetration into new
markets
✓ Customer partnerships
✓ Operational excellence
✓ Hiring right talent
✓ Quality & compliance
culture
✓ Cutting edge technologies
✓ Good corporate governance
✓ Risk management
✓ Listening to customers’
needs
✓ Continuous learning
We aspire to reach revenues of >Rs.500 cr by 2025/26
29 29
Thank you
VIMTA LABS LIMITED
INVESTOR RELATIONS AT
Registered Office Plot
NSE: VIMTALABS
Vimta Labs Ltd.
Plot #142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051
BSE: 524394
ISIN: INE579C01029
Website: www.vimta.com
mdoffice@vimta.com
Siddesh Chawan Siddesh.Chawan@in.ey.com Advait Bhadekar Advait.Bhadekar@in.ey.com